A clinically feasible protocol of TCR gene editing to treat Multiple Myeloma without inducing GvHD

被引：0
|
作者：
Mastaglio, S. [1 ]
Genovese, P. [1 ]
Magnani, Z. [1 ]
Camisa, B. [1 ]
Landoni, E. [1 ]
Schiroli, G. [1 ]
Provasi, E. [1 ]
Lombardo, A. [1 ]
Reik, A. [2 ]
Cieri, N. [1 ]
Ponzoni, M. [1 ]
Ciceri, F. [1 ]
Bordignon, C. [3 ]
Holmes, M. [2 ]
Gregory, P. [2 ]
Naldini, L. [1 ]
Bonni, C. [1 ]
机构：
[1] Ist Sci San Raffaele, I-20132 Milan, Italy
[2] Sangamo Biosci, Richmond, CA USA
[3] Molmed, Milan, Italy
来源：
BONE MARROW TRANSPLANTATION | 2015年 / 50卷
关键词：
D O I：
暂无
中图分类号：
Q6 [生物物理学];
学科分类号：
071011 ;
摘要：
P050
引用
收藏
页码：S143 / S143
页数：1
相关论文
共 50 条
  • [41] Validation of the Nextseq 500 and Development of a High-Throughput NGS Pipeline for Identifying Clinically-Relevant Gene Variants in Multiple Myeloma Specimens
    Zielinska, Agnieszka K.
    Leigh, Kenton
    Gomez, Horacio
    Van Laar, Ryan K.
    BLOOD, 2015, 126 (23)
  • [42] CRISPR-Cas9 based gene editing of the immune checkpoint NKG2A enhances NK cell mediated cytotoxicity against multiple myeloma
    Bexte, Tobias
    Alzubi, Jamal
    Reindl, Lisa Marie
    Wendel, Philipp
    Schubert, Ralf
    Salzmann-Manrique, Emilia
    von Metzler, Ivana
    Cathomen, Toni
    Ullrich, Evelyn
    ONCOIMMUNOLOGY, 2022, 11 (01):
  • [43] LAG-3, but Not Tim-3, Disruption in TCR Gene Edited Human Memory Stem T Cells Enhance the Anti Tumor Activity Against Multiple Myeloma
    Cianciotti, Beatrice C.
    Camisa, Barbara
    Potenza, Alessia
    Magnani, Zulma
    Vavassori, Valentina
    Naldini, Luigi
    Ciceri, Fabio
    Genovese, Pietro
    Ruggiero, Eliana
    Bonini, Chiara
    MOLECULAR THERAPY, 2019, 27 (04) : 63 - 63
  • [44] Gene editing of the immune checkpoint nkg2a enhances allogenic nk cell mediated cytotoxicity against patient-derived primary multiple myeloma cells
    Bexte, T.
    Alzubi, J.
    Reindl, L. M.
    Wendel, P.
    Schubert, R.
    Salzmann-Manrique, E.
    Von Metzler, I.
    Cathomen, T.
    Ullrich, E.
    BONE MARROW TRANSPLANTATION, 2022, 57 (SUPPL 1) : 152 - 153
  • [45] Gene expression profiling (GEP) after short term in-vivo treatment identifies potential mechanisms of action of current drugs used to treat multiple myeloma.
    Shaughnessy, J
    Zhan, FH
    Kordsmeier, B
    Randolph, C
    McCastlain, K
    Barlogie, B
    BLOOD, 2002, 100 (11) : 208A - 208A
  • [46] Bone-Targeted Inhibition of Notch Signaling Blocks Tumor Growth and Prevents Bone Loss Without Inducing Gut Toxicity In Immunodeficient and Immunocompetent Murine Models of Established Multiple Myeloma
    Ferrari, Adam
    McAndrews, Kevin
    Nelson, Jessica
    Bell, James
    Roodman, G. David
    Bellido, Teresita
    Delgado-Calle, Jesus
    Srinivasan, Venkatesan
    Ebetino, Frank H.
    Boeckman, Robert K., Jr.
    JOURNAL OF BONE AND MINERAL RESEARCH, 2019, 34 : 32 - 32
  • [47] Comprehensive gene analysis on ex-vivo mitomycin-C treatment as a potential protocol for inducing unresponsiveness to islet engraftment: harmonized downregulation of multiple chemotaxis factors
    Sato, Naoya
    Anazawa, Takayuki
    Haga, Junichiro
    Kenjo, Akira
    Kimura, Takashi
    Marubashi, Shigeru
    Wada, Ikuo
    Mori, Tsutomu
    Gotoh, Mitsukazu
    XENOTRANSPLANTATION, 2015, 22 : S76 - S78
  • [48] COMPREHENSIVE GENE ANALYSIS ON EX-VIVO MITOMYCIN-C TREATMENT AS A POTENTIAL PROTOCOL FOR INDUCING UNRESPONSIVENESS TO ISLET ENGRAFTMENT: HARMONIZED DOWNREGULATION OF MULTIPLE CHEMOTAXIS FACTORS.
    Sato, Naoya
    Anazawa, Takayuki
    Haga, Junichiro
    Kenjo, Akira
    Kimura, Takashi
    Marubashi, Shigeru
    Wada, Ikuo
    Mori, Tsutomu
    Gotoh, Mitsukazu
    TRANSPLANTATION, 2015, 99 (11) : S124 - S125
  • [49] CARAMBA: a first-in-human clinical trial with SLAMF7 CAR-T cells prepared by virus-free Sleeping Beauty gene transfer to treat multiple myeloma
    Sabrina Prommersberger
    Michael Reiser
    Julia Beckmann
    Sophia Danhof
    Maximilian Amberger
    Patricia Quade-Lyssy
    Hermann Einsele
    Michael Hudecek
    Halvard Bonig
    Zoltán Ivics
    Gene Therapy, 2021, 28 : 560 - 571
  • [50] CARAMBA: a first-in-human clinical trial with SLAMF7 CAR-T cells prepared by virus-free Sleeping Beauty gene transfer to treat multiple myeloma
    Prommersberger, Sabrina
    Reiser, Michael
    Beckmann, Julia
    Danhof, Sophia
    Amberger, Maximilian
    Quade-Lyssy, Patricia
    Einsele, Hermann
    Hudecek, Michael
    Bonig, Halvard
    Ivics, Zoltan
    GENE THERAPY, 2021, 28 (09) : 560 - 571
12345